Ethical Profile
Mixed.
Not enough information to create an ethical profile.
Omeros Corporation.
OMER.US | Manufacture of pharmaceuticals, medicinal chemical and botanical products
Omeros Corporation is a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for both complement-mediated diseases and disorders of the central nervous system. The company's lead product is OMIDRIA (phenylephrine ...Show More
Similar Companies
Value Scores
Better Health for All0
-100100
Fair Money & Economic Opportunity0
-100100
Fair Pay & Worker Respect10
-100100
Fair Trade & Ethical Sourcing0
-100100
Honest & Fair Business0
-100100
Kind to Animals-40
-100100
No War, No Weapons0
-100100
Planet-Friendly Business0
-100100
Respect for Cultures & Communities0
-100100
Safe & Smart Tech0
-100100
Zero Waste & Sustainable Products0
-100100
Better Health for All
0
Insufficient evidence to determine a value score for Omeros Corporation regarding Better Health for All. No articles or relevant information found. A neutral score of 0 is assigned. Materiality Analysis: Company Summary (75-100 words): Omeros Corporation is a clinical-stage biopharmaceutical company focused on developing therapeutics for immunologic diseases, orphan indications, and disorders related to the complement system. Their lead product candidate, Narsoplimab, targets TA-TMA and is being investigated for COVID-19 related conditions. Other pipeline products address PNH, C3G, addictions, and movement disorders. Preclinical programs target MASP-2, MASP-3, and cancer therapies. The company is headquartered in Seattle, Washington. Peer Comparison (50-75 words): Compared to other biopharmaceutical companies, Omeros's focus on orphan diseases and complement-related disorders is relatively specialized. Many peers pursue broader therapeutic areas. Omeros's pipeline, if successful, could address unmet needs, positioning it favorably in terms of "Better Health for All" relative to companies with less innovative or accessible products. Materiality Assessment (1-2 clear sentences): Omeros's business model is fundamentally supportive of the "Better Health for All" value, with a high level of materiality, given its focus on developing treatments for serious diseases and orphan indications. Detailed Rationale (150-200 words): Omeros directly contributes to "Better Health for All" by developing and potentially commercializing therapies for diseases with significant unmet medical needs. Their focus on orphan indications like TA-TMA and PNH suggests a commitment to addressing conditions that may be overlooked by larger pharmaceutical companies. The development of treatments for addictions and compulsive disorders (OMS527) further aligns with this value by addressing mental health and substance abuse issues. Clinical trial ethics and transparency are crucial considerations for Omeros, as is ensuring accessibility and affordability of their therapies if approved. The company's R&D investments in novel therapies directly impact its potential to improve health outcomes. The extent to which Omeros actively pursues equitable access to its therapies, particularly for vulnerable populations, will further determine its alignment with this value. Value Interaction Notes (if applicable, 25-50 words): The pursuit of novel therapies may involve intellectual property considerations that could potentially conflict with maximizing access to medicines in low-income settings, creating a tension between innovation and affordability. Scoring Boundary Flags (if applicable, 25-50 words): A score significantly below average would be illogical, given the company's core mission to develop treatments for diseases. A score in the lowest quartile should trigger a re-evaluation of the company's actual impact.
Fair Money & Economic Opportunity
0
No evidence available to assess Omeros Corporation on Fair Money & Economic Opportunity.
Fair Pay & Worker Respect
10
In 2024, the CEO to median employee pay ratio was approximately 20.5 to 1, with the CEO's total compensation at $3,764,151 and the median employee compensation at $183,614.
1
None of the company's 202 full-time employees are represented by a labor union. 2
The company settled a False Claims Act suit for nearly $4 million in November 2012, which was filed in September 2009. 3
The company's Code of Business Conduct and Ethics, adopted in March 2013, prohibits retaliation against employees who report violations. 4
Fair Trade & Ethical Sourcing
0
No evidence available to assess Omeros Corporation on Fair Trade & Ethical Sourcing.
Honest & Fair Business
0
No evidence available to assess Omeros Corporation on Honest & Fair Business.
Kind to Animals
-40
Omeros Corporation conducted nonclinical studies in rats and non-human primates, including 13-week studies and drug-drug interaction safety studies.
1
These animal studies were routinely required by the U.S. Food and Drug Administration (FDA). 2
The company suspended a Huntington's clinical trial to further evaluate an observation from a nonclinical study in rats. 3
The company communicates with the FDA regarding nonclinical data. 4
No War, No Weapons
0
Omeros Corporation is a biopharmaceutical company. The provided articles do not contain specific, concrete data points regarding any of the 'No War, No Weapons' KPIs. There is no evidence of revenue from arms or defense contracts, R&D investment in dual-use technologies, sales to embargoed regimes, or peacebuilding investments.
1
While the company's Code of Business Conduct and Ethics mentions compliance with U.S. export controls, it does not provide quantitative data on sales or specific policies related to military applications. 2
Therefore, no KPIs can be scored based on the available evidence.Planet-Friendly Business
0
The provided articles do not contain any specific, concrete data points or facts related to Omeros Corporation's environmental performance.
1
There is no information available regarding greenhouse gas emissions, renewable energy usage, water consumption, waste diversion rates, environmental certifications for facilities, or any other environmental metrics. 2
Therefore, no KPIs under the 'Planet-Friendly Business' value can be scored based on the evidence provided.Respect for Cultures & Communities
0
No evidence available to assess Omeros Corporation on Respect for Cultures & Communities.
Safe & Smart Tech
0
Omeros Corporation has not experienced any cybersecurity incidents that have materially affected the company.
1
The company states it complies with major U.S. state privacy laws, including CCPA, VCDPA, CPA, CTDPA, UCPA, OCPA, TXDPSA, MTCDPA, IACDPA, DEPDPA, NEDPA, NHPA, NJDPA, TNIPA, MNCDPA, MDODPA, INCDPA, KYCDPA, RIDTPPA, and with UK and EU GDPR. 2
Omeros operates a cybersecurity training program for employees that includes required webinars and simulated phishing attacks. 3
The company has implemented data encryption and vulnerability management and patching as part of its cybersecurity measures. 4
Omeros also utilizes penetration testing firms to identify cybersecurity risks. 5
Zero Waste & Sustainable Products
0
No evidence available to assess Omeros Corporation on Zero Waste & Sustainable Products.
Own Omeros Corporation?
Upload your portfolio and see how all your holdings score across 11 ethical dimensions.
Audit My PortfolioAI-generated analysis based on publicly available data. Not financial advice. Ratings are expressions of opinion derived from automated models and may contain inaccuracies. See our Risk Disclosure for full details.